Group 1 - The board meeting of Shandong Xinchao Energy Co., Ltd. was held on August 29, 2025, with all 8 directors present [1][2] - The board approved the revised 2024 annual work report, which will be submitted to the 2024 annual shareholders' meeting [2][3] - The board also approved the revised 2024 financial settlement report, which has been reviewed by the audit committee and will be submitted to the shareholders' meeting [2][3] Group 2 - A proposal to establish an internal control audit department was approved to enhance internal management and protect investors' rights [2][3] - The board approved the 2025 semi-annual report and its summary, confirming compliance with regulatory requirements [2][3] - A special report on the storage and actual use of raised funds for the first half of 2025 was also approved [3][4] Group 3 - The company plans to hold the 2024 annual shareholders' meeting on September 19, 2025, with all proposals receiving unanimous support [3][4]

Group 1 - The board of directors of Shenyuan Biopharmaceutical (Shanghai) Co., Ltd. held its fourth meeting on August 29, 2025, with all nine directors present, ensuring the legality and validity of the resolutions made [1][2] - The board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results for the first half of 2025, with no false records or misleading statements [1][2] - The board also approved the special report on the use of raised funds from January to June 2025, stating that the use of funds complies with relevant regulations and that all projects funded by the initial public offering have been completed [2][3] Group 2 - The board agreed to disclose the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, with unanimous approval from all directors [3] - The board proposed to cancel the supervisory board and amend the company's articles of association, which is aimed at improving the corporate governance structure and aligning with the latest legal requirements [4][5] - The board decided to convene the second extraordinary general meeting of shareholders for 2025 on September 25, 2024, to discuss the cancellation of the supervisory board and other operational regulations [5][6]

证券代码：688062 证券简称：迈威生物 公告编号：2025-043 表决结果：3 票同意，0 票反对，0 票弃权。 迈威（上海）生物科技股份有限公司 第二届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈威（上海）生物科技股份有限公司（以下简称"公司"）第二届监事会 第十八次会议通知于 2025 年 8 月 19 日以书面方式送达全体监事，于 2025 年 8 月 29 日以现场结合通讯方式召开。会议由监事会主席楚键先生主持，会议应到 监事 3 人，实到监事 3 人。会议的召集、召开程序和方式符合《公司法》等法 律法规以及《迈威（上海）生物科技股份有限公司章程》（以下简称"公司章 程"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于公司<2025年半年度报告>及摘要的议案》 经审议，全体监事认为公司编制的《2025 年半年度报告》及摘要符合相关 法律法规、中国证监会及上海证券交易所的有关规定，并真实反映了公司 2025 年半年度的实际 ...

国泰海通证券股份有限公司 董事会薪酬考核与提名委员会工作规则 （以下简称《公司章程》）的规定，结合公 司实际情况，制定本规则。 第二条 委员会是董事会下设的专门委员会，对董事会负责，向董事会报 告工作。 第二章 人员构成与组织机构 第三条 委员会由三名以上董事组成，委员会成员应当具有与委员会职责 相适应的专业知识和工作经验，其中独立董事应占多数；委员会需委任至少一名 不同性别的董事；委员会委员由董事长提名，报董事会批准。 第一章 总则 第一条 为保障国泰海通证券股份有限公司（以下简称公司）董事会薪酬 考核与提名委员会（以下简称委员会）依法独立、规范、有效地行使职权，完善 公司治理结构，确保本委员会的工作效率和科学议事，根据《中华人民共和国公 司法》 《中华人民共和国证券法》 《证券公司监督管理条例》 《上市公司治理准则》 《证券公司治理准则》《香港联合交易所有限公司证券上市规则》等有关法律、 法规、部门规章、规范性文件以及公司股票上市地上市规则（以下合称相关规则） 和《国泰海通证券股份有限公司章程》 第四条 委员会设主任委员一名，由独立董事委员担任。主任委员由董事 长提名，报董事会批准。 第五条 委员的任期与 ...

General Principles - The company establishes the Risk Control Committee to ensure effective governance and risk management in accordance with relevant laws and regulations [1][2] - The committee is responsible to the board of directors and reports its work to the board [1] Composition and Organization - The Risk Control Committee consists of at least three directors with appropriate professional knowledge and experience [2] - The term of committee members aligns with their term as directors, and vacancies must be filled according to the established rules [2] Responsibilities - The main responsibilities of the Risk Control Committee include reviewing compliance and risk management policies, assessing major decisions' risks, and evaluating compliance reports [2][3] - The committee must discuss the effectiveness of risk management and internal control systems at least once a year and report findings to shareholders [3] Meetings and Procedures - The committee is required to hold at least two regular meetings per year, with provisions for special meetings as necessary [4][5] - Meeting notifications must be sent in advance, and a quorum of two-thirds of members is required for meetings to proceed [4][5] Decision-Making and Reporting - Decisions made by the committee require a majority vote and must be documented accurately in meeting records [6][7] - The committee's resolutions that require board approval must be submitted in writing for inclusion in the board's agenda [7]

Core Points - The article outlines the work system for independent directors in the annual report process of Tianchuang Fashion Co., Ltd, aiming to enhance corporate governance and internal control [1] - Independent directors are required to ensure the annual report is truthful, accurate, and complete, free from any misleading statements [1][2] Summary by Sections Responsibilities of Independent Directors - Independent directors must diligently fulfill their responsibilities and cooperate with the company to complete the annual report [1] - They should not be influenced by major shareholders or related parties, ensuring the integrity of the report [1] Communication and Reporting Mechanisms - The company must establish a reporting and communication mechanism to facilitate independent directors in exercising their duties [2] - Company personnel are required to cooperate and not obstruct independent directors from understanding the company's operations [2] Management Reporting - The management must timely report the company's operational status and significant matters to independent directors [2] - Independent directors should conduct on-site investigations regarding major issues [2] Audit Process - Before the annual audit, independent directors should communicate with the auditing firm to understand the audit arrangements [3] - After the preliminary audit opinion, independent directors must meet with the auditing firm to discuss any issues found during the audit [3] Focus Areas in Annual Report - Independent directors should pay attention to related party transactions and any changes in commitments in the annual report [3] - They must ensure that the decision-making process for board matters is compliant with regulations [3] Disagreements and External Consultation - If independent directors have objections to the annual report, they can independently hire external audit and consulting firms with majority consent [3] Final Responsibilities - Independent directors must ensure all necessary disclosures are made in the annual report [4] - They are required to sign a written confirmation of the report's content and disclose any disagreements [4] Confidentiality and Compliance - Independent directors have a confidentiality obligation during the annual report preparation and must prevent insider trading [5] - They must report any suspected illegal activities by the company or its executives to the board and relevant regulatory bodies [5] Implementation and Amendments - The board of directors is responsible for formulating, revising, and interpreting this system [6] - The system takes effect upon approval by the board [6]

Group 1 - The board of directors of Yibin Paper Co., Ltd. held its second meeting of the 12th session on August 28, 2025, to review various proposals, with all 8 directors participating in the voting process [1][2] - The board approved the full text and summary of the 2025 semi-annual report, which was reviewed by the audit committee and disclosed on the Shanghai Stock Exchange website [1] - A risk assessment report regarding Sichuan Yibin Wuliangye Group Financial Co., Ltd. was also approved and disclosed simultaneously on the Shanghai Stock Exchange website [1] Group 2 - The board approved a revised proposal for the "Major Decision, Important Personnel Appointment, Major Project Arrangement, and Large Amount Fund Operation System" to enhance corporate governance and risk control [2] - The board also approved a revision of the "Asset Impairment Provision and Write-off Management Measures (Trial)" to ensure accurate financial reporting and reflect the company's financial status and operating results [2]

证券代码：600622 股票简称：光大嘉宝 编号：临2025-054 表决结果：3 票赞成，0 票反对，0 票弃权。 具体内容详见上海证券交易所网站 http://www.sse.com.cn。 经公司监事会审核：公司 2025 年半年度报告的编制和审议程序 符合法律、法规、中国证监会和《公司章程》等有关规定；内容和格 式符合中国证监会和上海证券交易所的有关规定，所包含的信息能从 各个方面真实、准确、完整地反映出公司 2025 年半年度的经营管理 和财务状况；未发现参与 2025 年半年度报告编制和审议的人员有违 反保密规定的行为。 光大嘉宝股份有限公司 第十一届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 光大嘉宝股份有限公司（以下简称"公司"）第十一届监事会第 十七次会议于 2025 年 8 月 28 日下午以"现场+视频"相结合的方式 在嘉定新城大厦（上海市嘉定区依玛路 333 弄 1-6 号）会议室召开。 监事会全体成员出席了会议。会议由监事会主席朱维强先生主持。本 次会议的召集、召开符合 ...

证券代码：601825 证券简称：沪农商行 公告编号：2025-033 上海农村商业银行股份有限公司 监事会 2025 年第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 上海农村商业银行股份有限公司（以下简称"公司"）监事会 2025 年第四次会议于 2025 年 8 月 29 日以现场方式召开，会议通知及会议 文件已于 2025 年 8 月 19 日以电子邮件方式发出。本次会议由连柏林 外部监事召集并主持，应参会监事 5 人，实际参会监事 5 人。本次会 议符合《公司法》和《上海农村商业银行股份有限公司章程》（以下 简称" 《公司章程》"）关于召开监事会法定人数的规定，表决所形成 决议合法、有效。 会议审议并经表决通过以下议案： 一、关于公司 2025 年半年度报告及摘要的议案 表决情况为：同意 5 票，反对 0 票，弃权 0 票。 监事会认为，公司 2025 年半年度报告的编制和审议程序符合国 家法律、法规和《公司章程》等规定；报告内容真实、准确、完整地 反映了报告期内公司的经营管理和财务状况。 详见 ...

清源科技股份有限公司 证券代码：603628 证券简称：清源股份 公告编号：2025-055 债券代码：113694 债券简称：清源转债 清源科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 清源科技股份有限公司（以下简称"公司"）第五届监事会第九次会议于2025 年8月28日在公司会议室召开，会议由刘宗柳先生主持。会议应出席监事3人，实 际出席会议监事3人。会议采用现场表决与通讯表决相结合的方式进行。会议的 召集和召开程序符合《中华人民共和国公司法》和《公司章程》的规定，所形成 的决议合法有效。 二、监事会会议审议情况 (一) 审议并通过《关于2025年半年度报告及摘要的议案》 公司监事会根据中国证监会《公开发行证券的公司信息披露内容与格式准则 第 3 号〈半年度报告的内容与格式〉》 《上海证券交易所股票上市规则》等有关规 定，对董事会编制的公司《2025 年半年度报告》及《2025 年半年度报告摘要》 进行了严格的审核，并提出了如下的书面审核意见，全体监事一致认为： 公司《2025 ...